Clinical trial · Interventional
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28: Prospective, Phase II, Multicenter Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects of giving combination chemotherapy together with bevacizumab and to see how well it works in treating patients with metastatic colorectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bevacizumab | Biological | Bevacizumab | ALIAS |
| fluorouracil | Drug | Fluorouracil | ALIAS |
| irinotecan hydrochloride | Drug | Irinotecan | ALIAS |
| leucovorin calcium | Drug | Leucovorin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FOLFIRI fort plus bevacizumab
- description
- Bevacizumab 5 mg/kg D1, irinotecan 260 mg/m2 D1, LV 400 mg/m2 D1, 5FU 400 mg/m2 IV bolus D1, and 5FU 2,400 mg/m2 46-hour infusion D1-2 every 2 weeks. Treatment was started within 2 weeks after inclusion in the study.
- interventionNames
- Biological: bevacizumab
- Drug: fluorouracil
- Drug: irinotecan hydrochloride
- Drug: leucovorin calcium
Primary outcomes (2)
- measure
- Objective response at 6 months by RECIST
- timeFrame
- 6 months
- measure
- Tolerability evaluated by NCI CTC v. 2.0 criteria
- timeFrame
- From Inclusion
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 74 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of metastatic adenocarcinoma of the colon or rectum * Not curable by surgery * Genotype UGT1A1\*1/UGT1A1\*1 or UGT1A1\*1/ UGT1A1\*28 * Measurable disease * No original tumor in place * No secondary cerebral metastases PATIENT CHARACTERISTICS: Inclusion criteria: * WHO performance status 0-2 * Life expectancy ≥ 3 months * Absolute neutrophil count ≥ 1,500/mm3 * Platelet count ≥ 100,000/mm3 * Hemoglobin ≥ 9.0 g/dL * Total bilirubin ≤ 1.5 times normal * Alkaline phosphatase ≤ 2.5 times normal (5 times normal if liver involvement) * Not pregnant or nursing * Negative pregnancy test * Fertile patients of must use effective contraception Exclusion criteria: * Progressive gastrointestinal ulcer, hemorrhagic ulcer, or perforation in the past 6 months * Enteropathy or chronic diarrhea * Proteinuria \> 500 mg/24 hours * Active cardiac disease * Uncontrolled hypertension * Myocardial infarction in the past 12 months * Angina * NYHA grade II-IV congestive heart disease * Severe arrhythmia even with treatment * Peripheral vascular disease ≥ grade II * Nonhealing wound, ulcer, or severe bone fracture * Hemorrhagic diatheses or coagulopathy * Severe or uncontrolled infection * Severe or uncontrolled medical condition * Other malignant disease in the past 5 years except curatively treated basal cell skin cancer or carcinoma in situ of the uterine cervix * Severe traumatic injury within the past 4 weeks PRIOR CONCURRENT THERAPY: * No prior chemotherapy for metastatic disease * One prior regimen of chemotherapy in the neoadjuvant or adjuvant setting for the original tumor allowed * At least 6 months since prior chemotherapy * No prior irinotecan hydrochloride or bevacizumab * No oral or parenteral anticoagulant therapy within the past 10 days * Warfarin allowed provided INR \< 1.5 * No major surgery or biopsy within the past 4 weeks * No puncture in the past 7 days * No planned major surgery * No concurrent daily or chronic aspirin (\> 325 mg/day), anti-inflammatories, or steroids * No other concurrent anticancer therapy
References
Publications (1)
- RESULTManfredi S, Bouche O, Rougier P, Dahan L, Loriot MA, Aparicio T, Etienne PL, Lafargue JP, Lecaille C, Legoux JL, Le Malicot K, Maillard E, Lecomte T, Khemissa F, Breysacher G, Michel P, Mitry E, Bedenne L. High-Dose FOLFIRI plus Bevacizumab in the Treatment of Metastatic Colorectal Cancer Patients with Two Different UGT1A1 Genotypes: FFCD 0504 Study. Mol Cancer Ther. 2015 Dec;14(12):2782-8. doi: 10.1158/1535-7163.MCT-15-0293. Epub 2015 Oct 22. PMID 26494856